SOUTH SAN FRANCISCO,
July 30, 2019 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that it will report its second quarter 2019 financial
results after market close on Tuesday,
August 6, 2019. Rigel senior management will follow
the announcement with a live conference call and webcast at
4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial
results and give a company update.
Participants can access the live conference call by dialing
(877) 407-8309 (domestic) or (201) 689-8057 (international).
The conference call and accompanying slides will also be webcast
live and can be accessed from Rigel's website at
www.rigel.com. The webcast will be archived and available for
replay for 90 days after the call via the Rigel website.
About Rigel (www.rigel.com)
Rigel
Pharmaceuticals, Inc., is a biotechnology company dedicated to
discovering, developing and providing novel small molecule drugs
that significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate), the only
oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of
adult patients with chronic immune thrombocytopenia who have had an
insufficient response to a previous treatment. Rigel's clinical
programs include a Phase 3 study of TAVALISSE in warm autoimmune
hemolytic anemia (AIHA) and a Phase 1 study of R835, a proprietary
molecule from its interleukin receptor associated kinase (IRAK)
program. In addition, Rigel has product candidates in clinical
development with partners BerGenBio ASA, Daiichi Sankyo, Aclaris
Therapeutics, and AstraZeneca.
Please see www.TAVALISSE.com for the full Prescribing
Information.
Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2019-financial-results-300892760.html
SOURCE Rigel Pharmaceuticals, Inc.